Donor graft size, age and sex of patient affects ECD

Article

Increased donor graft size, younger donor age, and being female donor were linked to higher endothelial cell density (ECD) in patients who underwent penetrating keratoplasty for endothelial dysfunction conditions

Increased donor graft size, younger donor age, and being female donor were linked to higher endothelial cell density (ECD) in patients who underwent penetrating keratoplasty for endothelial dysfunction conditions, according to a study in the Archives of Ophthalmology.

Dr Jonathon H. Lass et al., Department of Ophthalmology and Visual Sciences, Case Western Reserve University and University Hospitals Eye Institute, Cleveland, Ohio, USA, conducted an investigation on a collection of Cornea Donor Study participants. A central reading center was used to determine preoperative and postoperative endothelial cell densities (ECDs). To identify the baseline factors related to ECD multivariate regression analyses were performed.

The median endothelial cell loss after 5 years was found to be 68% for grafts measuring 8.0 to 9.0 mm, 75% for grafts 7.0 mm to 8.0 mm in diameter and 74% for grafts 8.0 mm in diameter. Female donors demonstrated a 67% cell loss compared to a 72% cell loss amongst male donors. Factors not significantly associated with long-term ECD changes included method of tissue retrieval, donor cause of death, history of diabetes, and time from death to preservation or to surgery.

It was concluded that a larger donor graft size and being a younger, female donor was linked to higher ECD. The findings suggest the possibility of similar links that could exist after endothelial keratoplasty.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.